This week former CEO of CME TR Danny Corrigan joins the virtual studio team to review what went well with SFTR over the first weeks since launch, how the UTI issue is working out, where the problems with varying cash and collateral valuations might come from, and whether NCAs will be as flexible about SFTR as they were about EMIR when that first rolled out. Plus we report on how our clients have responded to the challenges of the new regulation...